NCT06717204Not yet recruiting
Vericiguat for Heart Failure With Reduced Ejection Fraction After Myocardial Infarction
Vericiguat for Ventricular Remodeling in Patients With Heart Failure With Reduced Ejection Fraction After Myocardial Infarction
Source: ClinicalTrials.gov · Last updated 4 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The effects of vericiguat on cardiac remodeling in patients with chronic stable heart failure after myocardial infarction have not been reported. This project aims to clarify the efficacy and safety of vericiguat in patients with chronic heart failure after myocardial infarction. Patients with chronic stable heart failure with reduced ejection fraction after myocardial infarction in the electronic medical records of Qilu Hospital of Shandong University will be selected and divided into two groups: the treatment group received vericiguat in addition to conventional treatment and the control group received conventional treatment only. After 12-month treatment, the effects of vericiguat on cardiac remodeling and function and cardiovascular adverse events will be evaluated. The results are helpful to provide a new treatment strategy for chronic heart failure after myocardial infarction.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 210 (estimated)
- First submitted
- 1 Dec 2024
- Start date
- 1 Jan 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Qilu Hospital of Shandong University
- Diseases
- Heart failure, Coronary artery disease
- NCT number
- NCT06717204
What you commit to
- Study type: Observational
- Planned participants: 210
- From 1 Jan 2025 to the primary completion date, 31 Dec 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with the following diseases: nonischemic cardiomyopathy; valvular heart disease; congenital heart disease; obstruction of left ventricular outflow tract; severe decompensated heart failure; active myocarditis or pericardial disease; end-stage liver and kidney diseases; malignant tumor;
- Mechanical complications of myocardial infarction;
Other
- Unable to obtain primary outcome data.
Who the study is looking for
- The history of acute myocardial infarction exceeds 3 months;
- Symptoms and signs of heart failure have been stable for more than one month;
- 18 years old or more;
- NYHA cardiac function classified as grade II\~IV;
- LVEF≤40%；
- NT-proBNP≥450pg/ml；
- All subjects or their guardians must sign the subject consent before entering the trial.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Shandong First Medical University/Shandong Province Qianfoshan Hospital Coordinator of this site? Confirm its status | Jinan | China | Unknown status |
| Qilu Hospital of Shandong University Coordinator of this site? Confirm its status | Jinan | China | Unknown status |
| Central Hospital Affiliated to Shandong First Medical University Coordinator of this site? Confirm its status | Jinan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.